GleamWall
中文EN

ACXP Acurx Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1736243 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY11.7%
TTM EPS YoY76.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-147.5%
ROA-98.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets29.0%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-15.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.12M$1.07M$341,468$281,807$429,691$524,210$598,798$825,059
SG&A expense$1.52M$1.24M$1.37M$1.34M$1.60M$1.75M$1.58M$1.97M
Operating income-$2.63M-$2.31M-$1.72M-$1.62M-$2.03M-$2.27M-$2.18M-$2.79M
Net income-$2.58M-$2.25M-$1.68M-$1.58M-$1.99M-$2.25M-$2.15M-$2.78M
EPS (basic)-0.49-0.53-0.62—-1.23-1.89-2.15—
EPS (diluted)-0.49-0.53-0.62—-1.23-1.89-2.15—
Weighted avg. shares (diluted)5.32M4.26M2.72M—1.63M1.19M1.00M—
Balance sheet
Cash & equivalents$9.65M$10.66M$9.25M$7.56M$5.91M$6.06M$4.64M$3.71M
Current assets—————$6.16M$4.81M$3.86M
Total assets$10.34M$10.98M$9.54M$7.69M$6.11M——$3.86M
Current liabilities$2.99M$2.83M$2.53M$2.42M$2.47M$2.59M$2.49M$3.24M
Total liabilities$2.99M$2.83M$2.53M$2.42M$2.47M$2.59M$2.49M$3.24M
Shareholders' equity$7.34M$8.15M$7.01M$5.27M$3.64M$3.57M$2.31M$615,121
Shares outstanding5.88M4.68M3.39M2.35M1.80M1.47M22.40M851,534
Cash flow statement
Operating cash flow-$2.49M-$1.71M-$1.41M-$1.18M-$1.88M-$1.67M-$2.05M-$2.25M
Financing cash flow$1.49M$3.11M$3.11M$2.83M$1.72M$3.09M$2.99M$194,547
Stock-based compensation$208,169$200,537$258,287$294,794$294,793$324,216$333,598$345,191

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.